Response to Weidhaas and Slack re: Comments on "The role of
KRAS
rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing"
Clin Cancer Res
.
2011 Oct 15;17(20):10.1158/1078-0432.CCR-11-1504.
doi: 10.1158/1078-0432.CCR-11-1504.
Authors
Harvey A Risch
,
Andrew Berchuck
,
Paul D P Pharoah
PMID:
24353399
PMCID:
PMC3863717
DOI:
10.1158/1078-0432.CCR-11-1504
No abstract available
Grants and funding
A6689/CRUK_/Cancer Research UK/United Kingdom